Browse MYLK

Summary
SymbolMYLK
Namemyosin light chain kinase
Aliases smMLCK; MYLK1; MLCK1; smooth muscle myosin light chain kinase; myosin, light polypeptide kinase; AAT7; KRP; ......
Chromosomal Location3q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm. Cell projection, lamellipodium. Cleavage furrow. Cytoplasm, cytoskeleton. Note=Localized to stress fibers during interphase and to the cleavage furrow during mitosis.
Domain PF00041 Fibronectin type III domain
PF07679 Immunoglobulin I-set domain
PF00069 Protein kinase domain
Function

Calcium/calmodulin-dependent myosin light chain kinase implicated in smooth muscle contraction via phosphorylation of myosin light chains (MLC). Also regulates actin-myosin interaction through a non-kinase activity. Phosphorylates PTK2B/PYK2 and myosin light-chains. Involved in the inflammatory response (e.g. apoptosis, vascular permeability, leukocyte diapedesis), cell motility and morphology, airway hyperreactivity and other activities relevant to asthma. Required for tonic airway smooth muscle contraction that is necessary for physiological and asthmatic airway resistance. Necessary for gastrointestinal motility. Implicated in the regulation of endothelial as well as vascular permeability, probably via the regulation of cytoskeletal rearrangements. In the nervous system it has been shown to control the growth initiation of astrocytic processes in culture and to participate in transmitter release at synapses formed between cultured sympathetic ganglion cells. Critical participant in signaling sequences that result in fibroblast apoptosis. Plays a role in the regulation of epithelial cell survival. Required for epithelial wound healing, especially during actomyosin ring contraction during purse-string wound closure. Mediates RhoA-dependent membrane blebbing. Triggers TRPC5 channel activity in a calcium-dependent signaling, by inducing its subcellular localization at the plasma membrane. Promotes cell migration (including tumor cells) and tumor metastasis. PTK2B/PYK2 activation by phosphorylation mediates ITGB2 activation and is thus essential to trigger neutrophil transmigration during acute lung injury (ALI). May regulate optic nerve head astrocyte migration. Probably involved in mitotic cytoskeletal regulation. Regulates tight junction probably by modulating ZO-1 exchange in the perijunctional actomyosin ring. Mediates burn-induced microvascular barrier injury; triggers endothelial contraction in the development of microvascular hyperpermeability by phosphorylating MLC. Essential for intestinal barrier dysfunction. Mediates Giardia spp.-mediated reduced epithelial barrier function during giardiasis intestinal infection via reorganization of cytoskeletal F-actin and tight junctional ZO-1. Necessary for hypotonicity-induced Ca(2+) entry and subsequent activation of volume-sensitive organic osmolyte/anion channels (VSOAC) in cervical cancer cells. Responsible for high proliferative ability of breast cancer cells through anti-apoptosis.

> Gene Ontology
 
Biological Process GO:0003012 muscle system process
GO:0006816 calcium ion transport
GO:0006936 muscle contraction
GO:0006939 smooth muscle contraction
GO:0006970 response to osmotic stress
GO:0006971 hypotonic response
GO:0007517 muscle organ development
GO:0010959 regulation of metal ion transport
GO:0014820 tonic smooth muscle contraction
GO:0030031 cell projection assembly
GO:0030335 positive regulation of cell migration
GO:0032060 bleb assembly
GO:0035904 aorta development
GO:0035909 aorta morphogenesis
GO:0040017 positive regulation of locomotion
GO:0043270 positive regulation of ion transport
GO:0048514 blood vessel morphogenesis
GO:0048644 muscle organ morphogenesis
GO:0048745 smooth muscle tissue development
GO:0048844 artery morphogenesis
GO:0051272 positive regulation of cellular component movement
GO:0051924 regulation of calcium ion transport
GO:0051928 positive regulation of calcium ion transport
GO:0060414 aorta smooth muscle tissue morphogenesis
GO:0060415 muscle tissue morphogenesis
GO:0060537 muscle tissue development
GO:0060840 artery development
GO:0061041 regulation of wound healing
GO:0070838 divalent metal ion transport
GO:0071214 cellular response to abiotic stimulus
GO:0071470 cellular response to osmotic stress
GO:0071476 cellular hypotonic response
GO:0072511 divalent inorganic cation transport
GO:0090303 positive regulation of wound healing
GO:1903034 regulation of response to wounding
GO:1903036 positive regulation of response to wounding
GO:2000147 positive regulation of cell motility
Molecular Function GO:0003779 actin binding
GO:0004674 protein serine/threonine kinase activity
GO:0004687 myosin light chain kinase activity
GO:0005516 calmodulin binding
Cellular Component GO:0001725 stress fiber
GO:0015629 actin cytoskeleton
GO:0030027 lamellipodium
GO:0031252 cell leading edge
GO:0032153 cell division site
GO:0032154 cleavage furrow
GO:0032155 cell division site part
GO:0032432 actin filament bundle
GO:0042641 actomyosin
GO:0097517 contractile actin filament bundle
GO:0097610 cell surface furrow
> KEGG and Reactome Pathway
 
KEGG hsa04020 Calcium signaling pathway
hsa04022 cGMP-PKG signaling pathway
hsa04270 Vascular smooth muscle contraction
hsa04510 Focal adhesion
hsa04611 Platelet activation
hsa04810 Regulation of actin cytoskeleton
hsa04921 Oxytocin signaling pathway
hsa04971 Gastric acid secretion
Reactome R-HSA-397014: Muscle contraction
R-HSA-195258: RHO GTPase Effectors
R-HSA-5627123: RHO GTPases activate PAKs
R-HSA-162582: Signal Transduction
R-HSA-194315: Signaling by Rho GTPases
R-HSA-445355: Smooth Muscle Contraction
Summary
SymbolMYLK
Namemyosin light chain kinase
Aliases smMLCK; MYLK1; MLCK1; smooth muscle myosin light chain kinase; myosin, light polypeptide kinase; AAT7; KRP; ......
Chromosomal Location3q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MYLK and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolMYLK
Namemyosin light chain kinase
Aliases smMLCK; MYLK1; MLCK1; smooth muscle myosin light chain kinase; myosin, light polypeptide kinase; AAT7; KRP; ......
Chromosomal Location3q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MYLK in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen Total # shRNA with >= 4-fold: 1 Resistant to T-cell proliferation
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolMYLK
Namemyosin light chain kinase
Aliases smMLCK; MYLK1; MLCK1; smooth muscle myosin light chain kinase; myosin, light polypeptide kinase; AAT7; KRP; ......
Chromosomal Location3q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MYLK in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.3260.453
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.1590.937
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.4410.751
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.4360.508
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.3430.911
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.5560.884
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0050.992
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.3220.846
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.3390.856
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.5410.772
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.8170.487
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.4380.0077
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MYLK in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.48.2-0.81
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.410.2-2.81
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.817.6-12.80.307
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86016.7-16.70.429
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.718.2-10.50.576
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.97.40.51
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221313.67.75.91
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolMYLK
Namemyosin light chain kinase
Aliases smMLCK; MYLK1; MLCK1; smooth muscle myosin light chain kinase; myosin, light polypeptide kinase; AAT7; KRP; ......
Chromosomal Location3q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MYLK. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMYLK
Namemyosin light chain kinase
Aliases smMLCK; MYLK1; MLCK1; smooth muscle myosin light chain kinase; myosin, light polypeptide kinase; AAT7; KRP; ......
Chromosomal Location3q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MYLK. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MYLK.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMYLK
Namemyosin light chain kinase
Aliases smMLCK; MYLK1; MLCK1; smooth muscle myosin light chain kinase; myosin, light polypeptide kinase; AAT7; KRP; ......
Chromosomal Location3q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MYLK. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMYLK
Namemyosin light chain kinase
Aliases smMLCK; MYLK1; MLCK1; smooth muscle myosin light chain kinase; myosin, light polypeptide kinase; AAT7; KRP; ......
Chromosomal Location3q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MYLK expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMYLK
Namemyosin light chain kinase
Aliases smMLCK; MYLK1; MLCK1; smooth muscle myosin light chain kinase; myosin, light polypeptide kinase; AAT7; KRP; ......
Chromosomal Location3q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MYLK and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMYLK
Namemyosin light chain kinase
Aliases smMLCK; MYLK1; MLCK1; smooth muscle myosin light chain kinase; myosin, light polypeptide kinase; AAT7; KRP; ......
Chromosomal Location3q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MYLK collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.